Want to see SG:1H3 full AI Analyst Report?
1H3 Stock Chart & Stats
S$0.01
S$0.00(0.00%)
At close: 4:00 PM EDT
S$0.01
S$0.00(0.00%)
Day’s Range― - ―
52-Week Range<S$0.01 - S$0.02
Previous CloseN/A
Volume0.00
Average Volume (3M)N/A
Market Cap
S$12.89M
Enterprise ValueS$5.52
Total Cash (Recent Filing)S$4.12M
Total Debt (Recent Filing)S$703.00K
Price to Earnings (P/E)―
Beta0.26
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,443,731,400
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.91
Price to Sales (P/S)0.66
P/FCF Ratio-2.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue RecoveryA 33.9% revenue rebound and stabilization near S$9.9m indicate improving demand for core screening and diagnostic services. Durable patient and corporate program demand can support gradual margin recovery if operating costs are controlled and utilization remains steady over the next several quarters.
Manageable LeverageRelatively low absolute debt versus equity suggests limited near-term creditor pressure and some financial flexibility. Manageable leverage gives the company time to execute operational fixes or secure growth capital without immediate solvency stress, supporting medium-term stability if cash burn is addressed.
Diversified Service ModelA business mix of individual health screenings, diagnostic tests and corporate wellness contracts creates multiple revenue channels and cross-sell opportunities. Structural demand for preventive healthcare and employer-sponsored programs supports recurring revenue potential and long-term resiliency versus single-product providers.
Bears Say
Structural UnprofitabilityConsistent multi-year net losses, with a material widening in 2025, show the business has not yet achieved scale or cost structure to generate sustainable profits. Persistent unprofitability erodes equity, limits reinvestment capacity, and demands a credible operational turnaround to avoid long-term value destruction.
Chronic Cash BurnContinuous negative operating and free cash flow increases funding risk and constrains the company’s ability to invest in capacity or product improvements. Ongoing cash consumption makes the firm dependent on external financing, which can dilute shareholders or limit strategic options over the medium term.
Weakened Balance Sheet & ROE PressureDeclining equity and asset bases alongside historically negative ROE indicate capital erosion and diminished capacity to absorb shocks. This deterioration impairs the company's ability to finance growth internally and reduces investor confidence in its ability to restore positive shareholder returns over time.
Clearbridge Health Ltd. News
1H3 FAQ
What was Clearbridge Health Ltd.’s price range in the past 12 months?
Clearbridge Health Ltd. lowest share price was <S$0.01 and its highest was S$0.02 in the past 12 months.
What is Clearbridge Health Ltd.’s market cap?
Clearbridge Health Ltd.’s market cap is S$12.89M.
When is Clearbridge Health Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Clearbridge Health Ltd.’s earnings last quarter?
Currently, no data Available
Is Clearbridge Health Ltd. overvalued?
According to Wall Street analysts Clearbridge Health Ltd.’s price is currently Overvalued.
Does Clearbridge Health Ltd. pay dividends?
Clearbridge Health Ltd. does not currently pay dividends.
What is Clearbridge Health Ltd.’s EPS estimate?
Clearbridge Health Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Clearbridge Health Ltd. have?
Clearbridge Health Ltd. has 6,443,731,400 shares outstanding.
What happened to Clearbridge Health Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Clearbridge Health Ltd.?
Currently, no hedge funds are holding shares in SG:1H3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Clearbridge Health Ltd.
Established in 2010 and headquartered in Singapore, Clearbridge Health Limited operates as an investment holding company, delivering diverse healthcare solutions globally, including in Singapore, the Philippines, Hong Kong, and Malaysia. The firm's activities are organized into three key divisions: Strategic Investments, Healthcare Systems, and Medical Clinics/Centres. Its extensive range of services encompasses advanced imaging diagnostics, such as general X-ray, CT scans (including dental cone beam), mammography, MRI, and ultrasound. Furthermore, Clearbridge offers general wellness screenings for conditions like diabetes, high blood pressure, and elevated cholesterol, alongside vaccination programs. Specialized care includes renal treatment, clinical services, aesthetic procedures, and dental and orthodontic services. Beyond patient care, the company provides consultancy to healthcare organizations and is involved in the wholesale supply of medicinal and pharmaceutical products.
Asiamedic Limited
―
AJJ Medtech Holdings Limited
―
Alliance Healthcare Group Ltd.
―
Medinex Ltd.
―
Quantum Healthcare Ltd.
―